5 Key Takeaways

• 1

  Single-tablet and multi-tablet HIV regimens showed similar rates of viral suppression in Washington state Medicaid enrollees.

• 2

  Viral suppression was 91.6% for the single-tablet regimen compared to 88.9% for multi-tablet regimens, but the difference was not statistically significant.

• 3

  Housing status significantly impacted viral suppression rates, with lower suppression among those experiencing unstable housing.

• 4

  Bictegravir/emtricitabine/tenofovir alafenamide is approximately 77% more expensive than some dolutegravir-based multi-tablet alternatives.

• 5

  The study suggests a need for a holistic approach to HIV treatment that considers effectiveness, cost, and patient preferences.